Ibrutinib Combined With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results From the Randomized Phase 3 SYMPATICO Study

News
Video

Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).

Related Videos
William B. Pearse, MD
William B. Pearse, MD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Andre Goy, MD
Tycel Phillips, MD
Andre Goy, MD
Related Content
MCL | Image Credit: ©freshidea - stock.adobe.com

Zanubrutinib Associated With Longer Treatment Persistence, Duration, and TTD in Real-World MCL

April 17th 2024
Article
Lori A. Leslie, MD

FDA Approval Insights: Pirtobrutinib in MCL

February 27th 2023
Podcast
CTL019 in MCL| Image Credit: © Dr_Microbe - stock.adobe.com

CTL019 Plus Ibrutinib is Feasible and Effective in Relapsed/Refractory MCL

March 29th 2024
Article
Joshua Brody, MD

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

December 8th 2022
Podcast
Cancer in the blood outbreak and treatment for malignant cells in a human body caused by carcinogens and genetics with a cancerous cell as an immunotherapy and leukemia or lymphoma symbol and medicalImage Credit: © freshidea - stock.adobe.com

Brexu-Cel Displays Superior Responses vs Pirtobrutinib in Relapsed/Refractory MCL Matching-Adjusted Indirect Comparison

March 22nd 2024
Article
Cancer in the blood outbreak and treatment for malignant cells in a human body caused by carcinogens and genetics with a cancerous cell as an immunotherapy and leukemia or lymphoma symbol and medicalImage Credit: © freshidea - stock.adobe.com

EZH2 Expression and TP53 Mutation Results in Inferior Outcomes in MCL

March 21st 2024
Article